In this deep-dive episode, we unpack Anxiety Treatment Beyond SSRIs: A PMHNP Prescribing Guide for 2026. SSRIs remain first-line for anxiety disorders, but many patients need alternatives due to inadequate response, intolerable side effects, or comorbid conditions. This guide covers evidence-based second-line and augmentation strategies including buspirone, hydroxyzine, gabapentinoids, SNRIs, and emerging options PMHNPs should have in their clinical toolkit. Read the full post: https://psychnpfellowship.com/anxiety-treatment-beyond-ssris-pmhnp-prescribing-guide-2026/